Affymetrix Inc. (AFFX)

[jones99]

Affymetrix (AFFX) said its board will engage in discussions with Origin regarding its unsolicited proposal submitted on March 22nd to buy the company for $17 per share in cash. This comes despite Affymetrix continuing to recommend that its shareholders adopt its merger agreement with Thermo Fisher (TMO).

[jones99]

Affymetrix (AFFX) said a proposal made by Origin Technologies to buy the company for $16.10 per share or $1.5 billion in total does not constitute a superior proposal to Thermo Fisher’s (TMO) $1.3 billion acquisition offer. The determination is premised on the predator’s inadequate source of financing for the deal.

[stocktrademan]

$AFFX recent news/filings

bullish 15.99
buyout offer of 16.10

## source: finance.yahoo.com

$AFFX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$AFFX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AFFX/company-info
Ticker: $AFFX
OTC Market Place: Not Available
CIK code: 0000913077
Company name: Affymetrix, Inc.
Incorporated In: DE, USA

$AFFX share structure

## source: otcmarkets.com

Market Value: $1,129,188,381 a/o Mar 17, 2016
Shares Outstanding: 80,541,254 a/o Feb 11, 2016
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$AFFX extra dd links

Company name: Affymetrix, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AFFX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AFFX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AFFX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/news - http://finance.yahoo.com/q/h?s=AFFX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AFFX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AFFX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AFFX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Affymetrix%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Affymetrix%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Affymetrix%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AFFX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000913077&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AFFX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AFFX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AFFX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AFFX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AFFX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AFFX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AFFX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AFFX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AFFX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AFFX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AFFX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AFFX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AFFX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AFFX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AFFX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AFFX



$AFFX DD Notes ~ http://www.ddnotesmaker.com/AFFX

[rainbow898]

Shop@Arrayit!

[stocktrademan]

$AFFX DD Notes ~ http://www.ddnotesmaker.com/AFFX

bullish

$AFFX recent news/filings

## source: finance.yahoo.com

Mon, 15 Dec 2014 10:49:27 GMT ~ Alder Biopharmaceuticals Slumps: ALDR Falls 5.5% in Session


read full: http://finance.yahoo.com/news/alder-biopharmaceuticals-slumps-aldr-falls-104927254.html
*********************************************************

Fri, 12 Dec 2014 10:47:25 GMT ~ Celladon Corporation (CLDN) Falls: Stock Goes Down 8.6%


read full: http://finance.yahoo.com/news/celladon-corporation-cldn-falls-stock-104725363.html
*********************************************************

Wed, 10 Dec 2014 10:57:26 GMT ~ Kite Pharma (KITE) Shows Strength: Stock Moves Up 16.4%


read full: http://finance.yahoo.com/news/kite-pharma-kite-shows-strength-105726238.html
*********************************************************

Wed, 10 Dec 2014 10:53:30 GMT ~ Celladon Corp. (CLDN) Jumps: Stock Adds 14.7% in Session


read full: http://finance.yahoo.com/news/celladon-corp-cldn-jumps-stock-105330404.html
*********************************************************

Tue, 09 Dec 2014 11:43:21 GMT ~ eBioscience, an Affymetrix Business, Launches the First Assay to Detect RNA and Protein Simultaneously in Millions of Single Cells

[at noodls] - SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec. 9, 2014-- eBioscience, an Affymetrix (Nasdaq:AFFX) business, announces the availability of PrimeFlow™ RNA Assay, the first and only flow cytometry assay capable ...

read full: http://www.noodls.com/view/78707A3285DA83B5EA67B01D5F1E83903EDAE922
*********************************************************


$AFFX charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$AFFX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/AFFX/company-info
Ticker: $AFFX
OTC Market Place: Not Available
CIK code: 0000913077
Company name: Affymetrix, Inc.
Incorporated In: DE, USA


$AFFX share structure

## source: otcmarkets.com

Market Value: $740,618,823 a/o Dec 26, 2014
Shares Outstanding: 73,583,589 a/o Oct 27, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$AFFX extra dd links

Company name: Affymetrix, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AFFX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AFFX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AFFX+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/news - http://finance.yahoo.com/q/h?s=AFFX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AFFX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AFFX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AFFX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Affymetrix%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Affymetrix%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Affymetrix%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AFFX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000913077&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AFFX&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AFFX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AFFX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AFFX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AFFX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AFFX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AFFX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AFFX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AFFX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AFFX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AFFX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AFFX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AFFX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AFFX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AFFX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AFFX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AFFX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AFFX



$AFFX DD Notes ~ http://www.ddnotesmaker.com/AFFX

[Mithrandir67]

is this a change in trend now turning upwards?
Let's hope for it.

MIT

[Mithrandir67]

still continuous down movement. Waiting and hoping for a correction and hopefully turn to an upward movement.

MIT

[TheFinalCD]

Affymetrix Receives FDA Clearance of First-of-its-kind Postnatal Test for Developmental Delays and Intellectual Disabilities in Children

CytoScan® Dx Assay represents a technology leap over traditional postnatal genetic tests and significantly improves diagnostic capability

SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 21, 2014-- Affymetrix, Inc. (NASDAQ: AFFX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan® Dx Assay. This assay is intended for the postnatal detection of DNA copy number variants (CNV) in patients referred for chromosomal testing. CytoScan Dx Assay is designed to help physicians diagnose children’s developmental and intellectual disabilities more comprehensively by enabling a high-resolution genome-wide analysis of genetic aberrations. High resolution analysis can reveal small aberrations not readily seen using traditional techniques.

“This clearance is first-of-its-kind, and represents a leap forward in molecular genetic testing. CytoScan Dx Assay is the first FDA-cleared test that analyzes the whole genome in a single assay at unprecedented resolution, which significantly improves diagnostic capability. Developing and clearing this assay establish Affymetrix as a leader in advancing molecular diagnostics by bringing high quality genomic tools into routine application in the clinic,” said Frank Witney, CEO and President of Affymetrix. “We expect to be making CytoScan Dx Assay available to laboratories within the US in the next few months. In addition, the clearance by the FDA is an important milestone for supporting adoption in other key countries around the world where they are now evaluating advanced tools and tests like this.”

"We are pleased to have been selected by Affymetrix to be part of the clinical trial for CytoScan Dx Assay and found the performance data of this assay very impressive. With two to three percent of children in the United States having some form of developmental delay or intellectual disabilities, finding a diagnosis for the patient and their family can become a lengthy odyssey. This assay represents the best option for accelerating an accurate diagnosis," said Alka Chaubey, PhD, Director of the Greenwood Genetic Center's Cytogenetics Laboratory.

For additional information on CytoScan Dx Assay, please email us at [e-mail]

PLEASE NOTE: Affymetrix, the Affymetrix logo, and CytoScan are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.

Forward-looking statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2012, and other SEC reports for subsequent quarterly periods.

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness.

The Company provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world.

More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.




Source: Affymetrix, Inc.

Affymetrix, Inc.
Media Contact:
Mindy Lee-Olsen
Vice President, Marketing Services
408-731-5523
[e-mail]
or
Investor Contact:
Doug Farrell
Vice President, Investor Relations
408-731-5285
[e-mail]

SOURCE: http://investor.affymetrix.com/phoenix.zhtml?c=116408&p=irol-newsArticle&ID=1892090&highlight=

[binks]

Looking good
52 week high
8 is coming soon

[binks]

I hopped on board

[mlkrborn]

Affymetrix Rise on Turnaround 2Q Earnings - Analyst Blog
Date : 08/07/2013 @ 12:25PM
Source : Zacks
Stock : Affymetrix, Inc. (MM) (AFFX)
Quote : 5.28 0.19 (3.73%) @ 4:38PM

Affymetrix Rise on Turnaround 2Q Earnings - Analyst Blog
Print
Alert

Shares of Affymetrix Inc.’s (AFFX) rose 6.4% to $5.00 yesterday following the release of its promising 2013-second quarter results on Jul 31. The company reported its first earnings since the first quarter of 2011. The stock price is very close to the 52-week high of $5.26 on Jul 12.

Affymetrix posted adjusted earnings per share of 4 cents in the quarter in sharp contrast to the year-ago adjusted loss of 13 cents. This reflected a whopping 500% earnings surprise compared with the Zacks Consensus Estimate of a loss of a penny.

Thanks to AFFX’s strategic restructuring plans and its acquisition of eBioscience in Jun 2012 that has opened new avenues for the company and turned its focus away from the beleaguered Gene Expression business.

Revenues increased 19.7% year over year to $79.5 million (including the eBioscience acquisition), almost in line with the Zacks Consensus Estimate. eBioscience revenues increased manifold to $18.8 million from $1.4 million in the year-ago period.

During the quarter, Affymetrix launched a new product, Axiom 384HT Genotyping Format, a high-throughput platform capable of genotyping 384 samples simultaneously and run on the GeneTitan Instrument.

We are impressed with Affymetrix’s strong second-quarter results, following a dismal first quarter. We believe that AFFX is ready for a turnaround due to management's strategy to transform it into a company with a broad reach in the high-growth markets for translational medicine, molecular diagnostics and applied markets. Despite a tight U.S. academic funding environment, AFFX’s new products and strategic agreements should propel growth in the company.

Currently, AFFX has a Zacks Rank #1 (Strong Buy). Other companies like Biogen Idec (BIIB), Gilead Sciences (GILD) and Actelion (ALIOF), all carrying a Zacks Rank #1 (Strong Buy), are also expected to do well in the Medical-Biomed/Gene industry.

ZACKS

[twoco]

this stock is going places, hop on board, before the train leaves the station. read all the reports that you can.

[ECole]

Q2 in detail

74.2 million of total revenues comprise the product sales
http://www.earningsimpact.com/Transcript/82719/AFFX/Affymetrix%2c-Inc----Q2-2013-Earnings-Call

[sempertrade]

Expect a slight upward correction today IMO

[surf1944]

6:06AM Affymetrix sees Q1 revs below consensus (AFFX) 4.66 : Co issues downside guidance for Q1 (Mar), sees Q1 revs of ~ $78 mln, including rev of ~ $19 mln from eBioscience, vs. $83.34 mln Capital IQ Consensus Estimate. "Our revenues for the first quarter were below expectations, primarily due to continued headwinds in our gene expression business across all regions, in particular Japan, where we came in significantly short of plan. Our genotyping and cytogenetics product lines generated solid growth for the quarter as compared to 2012 and eBioscience also had modest growth from the first quarter of last year. As reported earlier, we ended the quarter with a major win, securing the largest biobank genotyping study to date."

[surf1944]

9:16AM Affymetrix signs contract with UK Biobank to genotype 500,000 UK individuals in a study of genetic and environmental factors in disease and personalized medicine (AFFX) 4.66 : Co announced that it has signed a contract with UK Biobank to genotype 500,000 DNA samples donated by UK residents as part of a prospective epidemiological study of complex diseases that are of great relevance to public health. Affymetrix' Axiom Genotyping Solution will be used to generate billions of genotypes which will provide UK Biobank and the research community with valuable insight to genetic factors underlying human diseases for improved prevention, diagnosis, and treatment of conditions such as heart disease, cancer, and diabetes.

[surf1944]

Affymetrix Names GenoSplice as Its Preferred Data Analysis Service Provider Increasing Accessibility for Bioinformatics in Genomic Research

SANTA CLARA, Calif.--(BUSINESS WIRE)--
Affymetrix, Inc. (AFFX) announced a co-marketing agreement today naming GenoSplice, Inc. as its preferred data analysis service provider for the new GeneChip® Human Transcriptome Array 2.0, the most comprehensive microarray available for alternative splicing detection. GenoSplice, a leader in genomic data analysis and alternative splicing, has developed a dedicated expression analysis solution, EASANA®, including analysis for Affymetrix’ microarrays, such as GeneChip® Exon 1.0 ST Array, GeneChip® Human Transcriptome Array 1.0, and the new GeneChip® Human Transcriptome Array 2.0. When combined with GenoSplice analysis services, these arrays provide the highest resolution profiling of the transcriptome available on a microarray at both the gene and exon level.
“As part of Affymetrix’ commitment to provide end-to-end solutions, we are enabling those without access to bioinformatics to utilize the most powerful microarrays ever developed for the interrogation of alternative splicing events. Now with so many options open to researchers, it is increasingly more important to provide tools that generate biologically relevant results, not just data,” commented Kevin Cannon, SVP – Expression Business Unit at Affymetrix.
“We’re pleased to work with Affymetrix to combine two very powerful tools, Affymetrix’ high resolution microarrays for gene expression profiling of transcript isoforms and GenoSplice’s proprietary transcriptome data analysis service, to help researchers save valuable time so they can focus on the biology instead of on analytical details,” said Marc Rajaud, Co-CEO of GenoSplice. “GeneChip® Human Transcriptome Array 2.0 increases accessibility to genomic research, resulting in new data that have to be interpreted to be useful. Collaborating with Affymetrix helps keep GenoSplice on the forefront of developing dedicated tools that streamline and simplify genomic data analysis.”
PLEASE NOTE: Affymetrix®, the Affymetrix logo, and GeneChip® trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.
Products mentioned in this release are For Research Use only. Not for diagnostic procedures.
SOURCE: Affymetrix, Inc.
About GenoSplice
GenoSplice develops and globally markets unique high level bioinformatics analysis services for genomics data. The company provides in-house innovative solutions for integrated genomics and is unique in offering user-friendly support and long-term relationship for all next generation sequencing and microarray platforms. Each client as each analysis is unique. GenoSplice services mainly concern differential gene expression, alternative splicing, miRNA, fusion transcript, epigenetics, SNP, CNV, translocation and proteomics data. Visit www.genosplice.com for additional information.

[surf1944]

6:57AM Affymetrix and DNA Link sign partnership for forensic test development for human identification (AFFX) 3.81 : Co and DNA Link, a Korean genomics-based biotechnology co, announced that they have signed a Powered by AffymetrixTM (PbA) Program agreement in which DNA Link obtains a worldwide license to develop and commercialize a forensic test for comprehensive human identification and other diagnostic tests using Affymetrix' microarray technology and the Korea FDA (KFDA) cleared GeneChip System 3000Dx v.2.

[$hellKing]

This is another beautiful stock. Short term we will be heading much higher north. Price target at least $5.50

[surf1944]

http://investor.affymetrix.com/phoenix.zhtml?c=116408&p=irol-news&nyo=1

[surf1944]

Affymetrix 3Q Guidance Disappoints
ZacksBy Zacks Equity Research | Zacks – Sat, Oct 13, 2012 6:43 AM EDT

Genetic products company, Affymetrix Inc. (AFFX) recently provided its guidance for the third quarter 2012 results, based on available preliminary financial data. The company will be reporting the results on October, 31 after market closes.

Affymetrix expects revenues to be roughly $80 million in the third quarter of 2012, which is below the Zacks Consensus Estimate of $82 million. According to management, declining Euro as well as a difficult global academic funding backdrop is adversely affecting the gene expression and eBioscience unit, thereby constricting the company’s top-line growth.

The company’s share prices dropped 3.1% on October 9, following the disappointing guidance announcement. However, Affymetrix currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. We have a long-term ‘Neutral’ recommendation on the stock.

Affymetrix further stated that the eBioscience business, although integrating well into the company, did not perform up to the mark in the quarter and expects it to contribute $18 million to total revenues. The gene expression unit also disappointed. However, Affymetrix anticipates cytogenetics and genotyping products to grow at a double-digit rate in the reported quarter.

Overall, Affymetrix expects full year 2012 revenues to remain either flat or marginally down, led by Affymetrix’s exposure to the volatile funding environment and weakening Euro. Research and development (R&D) spending by Affymetrix’s customers have fallen considerably due to a weak macroeconomic environment coupled with stringent government actions including budget cuts.

Additionally, following an interest and principal payment of $3.5 million on senior debt, Affymetrix forecasts to generate cash-on-hand of $39.6 million (as of September 30, 2012). The company had ended the year-ago quarter with cash and cash equivalent of $32.4 million.

Affymetrix holds a leading position in the gene expression products and services market. Along with Illumina Inc. (ILMN), it is one of the two major providers of microarray technologies, primarily used in the field of genetic research.

The Zacks Consensus Estimates for the third quarter and full year 2012 are expected to be a loss of 3 cents and 12 cents per share, respectively.

Currently, Affymetrix is shifting its research and development (R&D) focus from discovery and exploration markets to the faster-growing validation and routine testing markets. The company reckons cytogenetics and cancer research as promising areas for expansion, representing market opportunities of roughly $200 million and $500 million, respectively.

[surf1944]

7:31AM Affymetrix announces expansion of Quantigene ViewRNA license for in vitro diagnostics and becomes exclusive licensee for chromogenic applications (AFFX) 4.19 : Co announced the expansion of its license agreement with Siemens (SI) Healthcare Diagnostics for the co's branched DNA technology whereby Affymetrix is the exclusive licensee for in situ products, including in vitro diagnostics. This expanded license grants Affymetrix rights to develop and sell in situ QuantiGene ViewRNA products, currently for research use only, in the in vitro diagnostic market. Additionally, this license includes exclusive rights to alkaline phosphatase conjugated oligonucleotides and their use in bDNA methods for in situ detection utilizing Fast Red substrates. In light of this expanded license, Affymetrix plans to commercialize a platform of total solutions involving an assay menu of chromogenic-based applications of the bDNA technology which provide highly sensitive, multiplex analyses in both brightfield and fluorescence microscopy and options for automation.

[surf1944]

Affymetrix Announces Research Collaboration with Massachusetts General Hospital to Validate and Develop New Oncology Biomarker Tests

Press Release: Affymetrix, Inc. – 14 minutes ago
SANTA CLARA, Calif.--(BUSINESS WIRE)--

Affymetrix, Inc. (AFFX) today announced a research collaboration and licensing agreement with Massachusetts General Hospital (MGH) to co-develop new cancer biomarker tests using the Affymetrix’ QuantiGene® ViewRNA Assay platform*, an in situ hybridization assay capable of single transcript in single-cell detection. As part of this agreement, Affymetrix has the rights to commercialize the new biomarker tests as an outcome of this collaboration.

“This agreement provides Affymetrix with an important opportunity to expand its QuantiGene ViewRNA Assay offering into the pathology and cancer research markets by providing new multiplex chromogenic in situ hybridization (CISH) and fluorescence in situ hybridization (FISH) RNA biomarker assays which are validated on clinical samples for research applications. Advanced in situ RNA hybridization methods applied to less invasive clinical samples such as FFPE core biopsies, FNAs, and CTCs has the potential of becoming powerful new tools to deliver diagnostics that enable the oncologist to personalize patient care,” stated George Bers, Vice President and General Manager, Gene Expression Business Unit Manager – Panomics at Affymetrix.

Currently, those who practice surgical pathology and cytology face challenges in the management of a broad range of cancers. Medical practitioners are optimistic that a solution to these challenges will be found in new biomarkers and drug targets which are being rapidly discovered by NGS and microarray technologies. Yet these new biomarker discoveries have in themselves become a challenge requiring extensive validation prior to becoming candidates for translation into diagnostic, prognostic, and predictive tests to fulfill the promise of delivering a new generation of personalized medicine and associated economic and healthcare outcomes.

"The future of cancer treatment lies in our ability to precisely identify specific biomarkers so we can then find effective drugs for that particular form of disease,” said Daniel A. Haber, MD, PhD, director of the MGH Cancer Center. “This collaboration with Affymetrix aims to move this important work forward."

MGH is a world leader in cancer research and education, translational medicine, and a major center for patient care. MGH has some of the world’s largest annotated tissue banks for retrospective biomarker studies as well as large and diverse patient populations for prospective studies. MGH’s Cancer Center and Department of Pathology are currently collaborating with Affymetrix to validate biomarkers of current and future clinical importance using Affymetrix’ QuantiGene ViewRNA technology platform for multiplex in situ testing of FFPE tissue biopsies, FNA cytologies, and CTC “liquid biopsies”. QuantiGene ViewRNA is an ideal platform for cancer biomarker validation and testing as RNA is a predictable, sensitive and specific alternative to antibody based IHC and ICC testing. QuantiGene ViewRNA probes for RNA assays can be developed for research applications for any expressed gene within days and can analyze non-coding RNAs believed to be important master regulators of cancer and for which antibody assays can’t be developed. To date, the research collaboration has produced several potential diagnostic/prognostic biomarker targets including new class of non-coding RNA, HSATII, and EGFR vIII.

[surf1944]

7:47AM On The Wires (WIRES) :Affymetrix (AFFX) and Leica Microsystems announced a world-wide collaboration that automates Affymetrix' QuantiGene ViewRNA ISH Tissue Assay on the Leica BOND RX staining platform for research applications

[surf1944]

7:34AM Affymetrix and ScreenCell announce worldwide distribution agreement for Circulating Tumor Cell technology (AFFX) 5.08 : Co and ScreenCell announced the signing of a worldwide distribution agreement for ScreenCell's isolation devices and dilution buffers, designed for the collection of Circulating Tumor Cells in peripheral blood. The agreement makes Affymetrix the exclusive distributor of ScreenCell products used in combination with in situ hybridization assays, microarray assays, and other non-PCR based nucleic acid assays including Affymetrix' QuantiGene ViewRNA Assays, QuantiGene Plex Assays, and GeneChip Microarray Assays. The QuantiGene ViewRNA CTC platform, consist of ScreenCell's products and Affymetrix' QuantiGene ViewRNA Assays, is now available from Affymetrix.

[surf1944]

1:11AM Affymetrix and eBioscience amend definitive merger agreement (AFFX) 4.33 : The amended agreement contemplates funding the acquisition using a combination of cash-on-hand, a senior secured financing of $75 mln and additional financing options available to the co. The senior secured financing, which includes an additional $15 mln revolving credit facility

[surf1944]

1:57AM On The Wires (WIRES) : Affymetrix (AFFX) announced that it has signed a global distribution agreement with Almac Group. In this agreement, Affymetrix has exclusive rights to distribute Almac's Xcel array for research use in biomarker discovery for multiple disease areas, including cancer.

[surf1944]

7:45AM On The Wires (WIRES) : Affymetrix (AFFX) announced that it has signed a global distribution agreement with Almac Group in which Affymetrix has exclusive rights to distribute Almac's Xcel array for research use in biomarker discovery for multiple disease areas, including cancer.

[mlkrborn]

Can AFFX be another AFFY? I think so!

Affymetrix (AFFX) and Lineagen announced that the cos have signed an agreement to incorporate Affymetrix' GeneChip technology into Lineagen's FirstStepDx, a genetic evaluation service for individuals with developmental delay, intellectual disability, and autism spectrum disorders. The FirstStepDx offering is anticipated to be available by mid-2012 and will feature a proprietary microarray-based assay incorporating genetic markers from recently concluded studies of more than 10,000 individuals.

[surf1944]

Affymetrix AFFX Stifel Nicolaus Buy $19

[surf1944]

6:12PM Affymetrix reports that China clears its first microarray platform for in vitro diagnostics to accelerate personalized medicine (AFFX) 4.63 +0.05 : Co announced that its GeneChip? System 3000Dx v.2 (GCS 3000Dx v.2) has been approved by China's State Food and Drug Administration (SFDA) for in vitro diagnostic use. The GCS 3000Dx v.2 is the first microarray instrument system to be granted SFDA registration for array-based diagnostics for enabling personalized medicine. China has more than 2,000 clinical centers that will now have access to the only SFDA-cleared microarray platform for clinical testing. The molecular diagnostic market in China is the fastest growing in the world and represents a significant growth opportunity for Affymetrix in Asia.

[Penny Roger$]

~ $AFFX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $AFFX ~ Earnings expected on Thursday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=AFFX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=AFFX&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/AFFX?
~ OTC Markets: http://www.otcmarkets.com/stock/AFFX/company-info
~ Google Finance: http://www.google.com/finance?q=AFFX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=AFFX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=AFFX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=AFFX
Finviz: http://finviz.com/quote.ashx?t=AFFX
~ BusyStock: http://busystock.com/i.php?s=AFFX&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=AFFX&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=AFFX
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=AFFX
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=AFFX
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=AFFX
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=AFFX
~ MarketWatch: http://www.marketwatch.com/investing/stock/AFFX/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=AFFX
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=AFFX
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=AFFX&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=AFFX&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=AFFX&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[surf1944]

15. Affymetrix Inc. (AFFX): Engages in the development, manufacture, sale, and servicing of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets. Market cap of $326.28M. Price (as of market close on 01/17) at $4.61. Net insider shares purchased over the last six months at 65.0K, which is 0.12% of the company's 56.19M share float. This is a risky stock that is significantly more volatile than the overall market (beta = 2.08). The stock is a short squeeze candidate, with a short float at 8.66% (equivalent to 6.01 days of average volume). The stock has had a couple of great days, gaining 7.42% over the last week.

http://seekingalpha.com/article/320484-20-stocks-under-5-being-snapped-up-by-insiders?source=yahoo

[mlkrborn]

Affymetrix and BGI Enter Strategic Collaboration to Co-Develop and Commercialize Genomic Microarrays for the Agricultural Community (AFFX) 4.66 : Co announces that it has signed a Memorandum of Understanding with BGI to enter into a strategic co-development and co-marketing collaboration. The non-exclusive partnership will aim to develop and commercialize a portfolio of plant, crop, and livestock microarrays for genotyping analysis, spanning applications such as marker-assisted trait selection, parentage, quality control, and traceability.

[mlkrborn]

Affymetrix to acquire privately-held eBioscience for $330 mln (AFFX) 4.63 : Co announces it has signed a definitive agreement to acquire eBioscience for $330 mln. Co states 2011 sales are expected to exceed $70 mln, gross margins in excess of 70% and EBITDA margin of ~30%. The purchase price represents ~4.5 times 2011 revenue and 14 times 2011 EBITDA. The transaction will be funded using a combination of roughly 50% cash-on-hand and 50% committed debt to avoid dilution.

[surf1944]

9:02AM Affymetrix enters an agreement with the Broad Institute to chart the genomic changes involved in more than 20 types of cancer as part of the Broad's work in The Cancer Genome Atlas (AFFX) 5.84 :

[surf1944]

http://www.secform4.com/insider-trading/913077.htm

[surf1944]

6:00AM Affymetrix announces Federal Court affirms dismissal of Illumina (ILMN) patent infringement lawsuits (AFFX) 4.57 : "We are pleased that the Federal Circuit has affirmed the District Court's prior rulings that Affymetrix does not infringe the asserted patents and dismissing Illumina's lawsuits," said Rick Runkel, Affymetrix's Executive Vice President, General Counsel and Secretary.

[surf1944]

4. Affymetrix Inc. (AFFX): Scientific & Technical Instruments Industry. Market cap of $398.33M. Short float at 12.03%. Over the last quarter, the stock fell at least 3% close-to-close on 5 occasions, with an average rebound of 3.83% over the following five days. This is a risky stock that is significantly more volatile than the overall market (beta = 2.17). It's been a rough couple of days for the stock, losing 16.79% over the last week.

http://seekingalpha.com/article/283764-6-highly-shorted-tech-stocks-with-a-recent-history-of-rebounds?source=yahoo

[mlkrborn]

AFFX drops $1.40s to $6.50s with earnings report:
Affymetrix stock skids on 2Q revenue outlook
Affymetrix slides after company says 2nd-quarter revenue will decline as academic demand falls



Related Quotes
Symbol Price Change
AFFX 6.60 -1.40

On Thursday July 7, 2011, 11:24 am

NEW YORK (AP) -- Shares of Affymetrix Inc. tumbled Thursday after the genetic testing instrument maker forecast disappointing second-quarter revenue.

THE SPARK: After the market closed on Wednesday, Affymetrix said its revenue will fall at least 9 percent in the second quarter. Its estimate of $64 million to $65 million was about $10 million less than analysts expected. Wall Street had expected the company's sales to improve from last year's $71.7 million.

THE BIG PICTURE: The Santa Clara, Calif., company said sales to academic customers decreased, especially in North America. Lower product revenue was responsible for most of the decline, as Affymetrix said those sales fell to about $58.5 million from $65.1 million a year ago

THE ANALYSIS: Robert W. Baird & Co. analyst Quintin Lai said a bad quarter is not a surprise given the company's recent CEO change. He said he thinks new President and CEO Frank Witney will focus on improving the company's revenue growth.

Witney's predecessor, Kevin King, left the company June 30. Affymetrix announced the change June 1, saying King was resigning to pursue other interests.

Lai reiterated an "Outperform" rating on the shares, but trimmed his price target to $10 per share from $11.

SHARE ACTION: Affymetrix stock dropped $1.47, or 18.4 percent, to $6.53.

[surf1944]

Affymetrix stock skids on 2Q revenue outlook
Affymetrix slides after company says 2nd-quarter revenue will decline as academic demand falls

On Thursday July 7, 2011, 11:24 am

NEW YORK (AP) -- Shares of Affymetrix Inc. tumbled Thursday after the genetic testing instrument maker forecast disappointing second-quarter revenue.

THE SPARK: After the market closed on Wednesday, Affymetrix said its revenue will fall at least 9 percent in the second quarter. Its estimate of $64 million to $65 million was about $10 million less than analysts expected. Wall Street had expected the company's sales to improve from last year's $71.7 million.

THE BIG PICTURE: The Santa Clara, Calif., company said sales to academic customers decreased, especially in North America. Lower product revenue was responsible for most of the decline, as Affymetrix said those sales fell to about $58.5 million from $65.1 million a year ago

THE ANALYSIS: Robert W. Baird & Co. analyst Quintin Lai said a bad quarter is not a surprise given the company's recent CEO change. He said he thinks new President and CEO Frank Witney will focus on improving the company's revenue growth.

Witney's predecessor, Kevin King, left the company June 30. Affymetrix announced the change June 1, saying King was resigning to pursue other interests.

Lai reiterated an "Outperform" rating on the shares, but trimmed his price target to $10 per share from $11.

SHARE ACTION: Affymetrix stock dropped $1.47, or 18.4 percent, to $6.53.

[surf1944]

Affymetrix AFFX Robert W. Baird Neutral » Outperform $6 » $11

Read more: http://www.briefing.com/investor/calendars/upgrades-downgrades/#ixzz1O7hphcub

[surf1944]

5:47AM Affymetrix achieves first FDA Clearance of microarray-based gene profiling reagents (AFFX) 6.16 : Co announces that the FDA has cleared the addition of new gene expression reagents as accessories to its GeneChip Microarray Instrument System for in vitro diagnostic use, making co the first in the industry to provide a comprehensive microarray-based clinical toolkit for diagnostic test development, signature discovery for companion diagnostics, and translational initiatives.

[surf1944]

Friday Options Brief: AFFX, AXP, WMG & MED

Affymetrix, Inc. (AFFX) – Call options on the biotechnology company are in demand today, with shares in the maker of genetic analysis products rising as much as 6.3% to an intraday high of $6.25. The jump in options activity on the stock helped lift the overall reading of options implied volatility on Affymetrix 17.9% to 73.54% in early-afternoon trade. June in- and out-of-the-money calls are most active on AFFX today. It looks like the June $5.0 strike calls were also popular with bullish players during trading on Thursday. Open interest patterns in the calls suggest investors purchased 2,100 contracts at the June $5.0 strike yesterday for a premium of $0.95 each.

The subsequent rally in the price of the underlying stock overnight combined with the sharp increase in implied volatility lifted the current asking price on the options to $1.50 each as of 1:25pm in New York. Options players hoping to see the price in Affymetrix shares continue to trend higher ahead of expiration day next month purchased the majority of the calls exchanged at the June $7.5 strike today. More than 2,000 calls changed hands at that strike on previously existing open interest of 561 contracts. The June $7.5 strike is the most heavily trafficked this afternoon, with buyers of the calls shelling out an average premium of $0.25 per contract for the options. Investors long the calls profit in the event that AFFX shares surge 24.0% over today’s high of $6.25 to surpass the average breakeven price of $7.75 by expiration day in June.

http://seekingalpha.com/article/268434-friday-options-brief-affx-axp-wmg-med?source=yahoo

[surf1944]

http://www.briefing.com/GeneralContent/Active/Investor/TickerSearch/QuickSearch.aspx

[surf1944]

Bullish Gene Dominant In Affymetrix Call Options
May. 6 2011 - 2:23 pm | 0 views | 0 recommendations | 0 comments
Posted by Caitlin Duffy
Affymetrix

Affymetrix

Today’s tickers: AFFX, AXP, WMG & MED
AFFX – Affymetrix, Inc. – Call options on the biotechnology company are in demand today, with shares in the maker of genetic analysis products rising as much as 6.3% to an intraday high of $6.25. The jump in options activity on the stock helped lift the overall reading of options implied volatility on Affymetrix 17.9% to 73.54% in early-afternoon trade. June in- and out-of-the-money calls are most active on AFFX today. It looks like the June $5.0 strike calls were also popular with bullish players during trading on Thursday. Open interest patterns in the calls suggest investors purchased 2,100 contracts at the June $5.0 strike yesterday for a premium of $0.95 each. The subsequent rally in the price of the underlying stock overnight combined with the sharp increase in implied volatility lifted the current asking price on the options to $1.50 each as of 1:25pm in New York. Options players hoping to see the price in Affymetrix shares continue to trend higher ahead of expiration day next month purchased the majority of the calls exchanged at the June $7.5 strike today. More than 2,000 calls changed hands at that strike on previously existing open interest of 561 contracts. The June $7.5 strike is the most heavily trafficked this afternoon, with buyers of the calls shelling out an average premium of $0.25 per contract for the options. Investors long the calls profit in the event that AFFX shares surge 24.0% over today’s high of $6.25 to surpass the average breakeven price of $7.75 by expiration day in June.
http://blogs.forbes.com/greatspeculations/2011/05/06/bullish-gene-dominant-in-affymetrix-call-options/?partner=yahootix

[surf1944]

Affymetrix's CEO Discusses Q1 2011 Results - Earnings Call Transcript

http://seekingalpha.com/article/266105-affymetrix-s-ceo-discusses-q1-2011-results-earnings-call-transcript?source=yahoo

[locksflooring]

Affymetrix Announces Court Order Directing Dismissal of Illumina Patent Infringement Lawsuits
Date : 12/15/2010 @ 5:00AM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 4.58 0.12 (2.69%) @ 7:59PM


Affymetrix Announces Court Order Directing Dismissal of Illumina Patent Infringement Lawsuits
Affymetrix (NASDAQ:AFFX)
Intraday Stock Chart
Today : Wednesday 15 December 2010
Affymetrix, Inc. (NASDAQ:AFFX) (the “Company”) today announced that the U.S. District Court for the Western District of Wisconsin (the “Court”) has granted the company’s motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc. (NASDAQ: ILMN), and has directed that the patent infringement lawsuits brought against the company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases closed.

“We are pleased with the Court’s ruling, which confirms our position that Illumina’s lawsuits were without merit,” said Rick Runkel, Affymetrix’s Executive Vice President, General Counsel and Secretary. “As a biotechnology company that invests significant time, resources and expertise in R&D, we are committed to conducting our business with the utmost integrity and believe that the Court’s ruling underscores this commitment.”

About Affymetrix

Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 22,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit http://www.affymetrix.com.

[locksflooring]

Affymetrix to Webcast Presentation at the 22nd Annual Piper Jaffray Health Care Conference
Date : 11/24/2010 @ 4:30PM
Source : Business Wire
Stock : Affymetrix, Inc. (AFFX)
Quote : 4.45 0.07 (1.60%) @ 10:20AM


Affymetrix to Webcast Presentation at the 22nd Annual Piper Jaffray Health Care Conference
Affymetrix (NASDAQ:AFFX)
Intraday Stock Chart
Today : Wednesday 24 November 2010
Affymetrix, Inc. (Nasdaq:AFFX) today announced that it will webcast the Company’s presentation at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1, 2010, at 1:30 p.m. EST.

A live webcast will be available at http://www.affymetrix.com under the "Investors" link. Archived webcasts will be available for 30 days.

About Affymetrix

Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 1,900 systems have been shipped around the world and more than 22,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Cleveland, Ohio, and Singapore. The company has about 1,000 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit http://www.affymetrix.com.

[mlkrborn]

Affymetrix swings to $1M Q3 profit
Silicon Valley / San Jose Business Journal
Date: Wednesday, October 27, 2010, 4:07pm PDT

Affymetrix Inc. on Wednesday reported third quarter net income of $1 million, or a penny a share, compared to a loss in the same period last year of $8.8 million, or 13 cents a share.

Santa Clara-based Affymetrix (NASDAQ:AFFX) had revenue of $74 million, down from the year-ago quarter's $78.2 million.

Product revenue was $67.3 million, service revenue was $4.9 million, and royalties and other revenue were $1.8 million. This compares to third quarter 2009 product revenue of $66.2 million, service revenue of $9.9 million, and royalties and other revenue of $2.1 million.

“We continue to move the business toward profitability through the adoption of new products, improvements in gross margins and by lowering operating expenses. During the third quarter we strengthened our balance sheet and significantly reduced future interest payments through the repurchase of approximately $72 million of our 3.50 percent senior convertible notes. Through the first nine months of 2010, we generated approximately $25 million in cash-flow from operations,” said CEO Kevin M. King.


Read more: Affymetrix swings to $1M Q3 profit | Silicon Valley / San Jose Business Journal